𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Treatment of relapsed and refractory acute myelogenous leukaemia with aclacinomycin A (ACA) and etoposide (VP-16)

✍ Scribed by Wolfgang Hilbe; Josef Thaler; Wolfgang Eisterer; Christof Ludescher; Dietger Niederwieser

Book ID
113239907
Publisher
Elsevier Science
Year
1994
Tongue
English
Weight
265 KB
Volume
18
Category
Article
ISSN
0145-2126

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Treatment of relapsed and refractory acu
Treatment of relapsed and refractory acute leukaemia with high-dose cytosine arabinoside and etoposide
✍ Martin Gore; Ray Powles; Anil Lakhani; Sarah Milan; Jennifer Maitland; Glen Goss πŸ“‚ Article πŸ“… 1989 πŸ› Springer 🌐 English βš– 425 KB

A total of 65 patients under the age of 55 with acute leukaemia received high-dose cytosine arabinoside (Ara-C) in combination with high-dose etoposide without an anthracycline. Complete remission rates for patients with relapsed or refractory acute myelogenous leukaemia (AML) were 15/25 (60%) and 1

Phase I study of VP-16 (etoposide) and a
Phase I study of VP-16 (etoposide) and amsacrine (AMSA) in the treatment of refractory acute leukemia
✍ Letendre, Louis ;Hinemann, Vicky ;Hoagland, H. Clark ;Kovach, John S. πŸ“‚ Article πŸ“… 1985 πŸ› John Wiley and Sons 🌐 English βš– 291 KB

Fourteen patients with refractory acute nonlymphocytic leukemia were entered into a doseseeking trial of combination therapy with etoposide and amsacrine given daily for five consecutive days. There were three complete responses lasting 2 months, 3 months, and 10 months and two transient partial rem